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Abstract 
 
Introduction: Inhaled ȕ2-agonists as bronchodilators are commonly used in Chronic Obstructive Pulmonary Disease (COPD). 
These drugs can be either short-acting (SABA) or long-acting (LABA). The aim of this retrospective study is to evaluate the use 
patterns of inhaled LABAs versus inhaled SABAs reimbursed in Albania during 2008-2012 for ambulatory COPD treatment. 
Methods: Data on analyzed drugs for COPD treatment were taken from Health Insurance Institute database. ATC/DDD 
methodology was used to quantify the consumption of inhaled ȕ2-agonists in DDD/1000 inhabitants/day and the results were 
expressed as percentage of annual drug use. All the data are calculated with Microsoft Office Excel program. Results: The 
utilization ratio of LABAs to SABAs was: 4:96 in 2008, 9.5:90.5 in 2009, 25:75 in 2010, 34:66 in 2011 and 45:55 in 2012 
respectively. During 2009-2012 the use of LABAs was increased, especially when they were in combination with inhaled 
corticosteroids (ICS). These combinations represented 5%, 18%, 24% and 23% of total annual consumption during four years 
respectively. In 2012 Salmeterol plus Fluticasone was the most used combination and Indicaterol was the most used among 
plain LABAs. Conclusion: The use of inhaled LABAs continually is increased versus SABAs ones for COPD treatment in 
Albanian insured outpatients during 2008-2012. These changes refered to the international guidelines wich recommend SABAs 
for as-needed symptom relief and LABAs as long-term maintenance therapies. In addition LABA/ICS combinations have 
greater efficacy than either of its components used alone.  
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1. Introduction 
 
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic morbidity and mortality throughout the 
world. COPD is characterized by persistent airflow limitation that is not fully reversible. The airflow limitation is usually 
progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious 
particles or gases.1 COPD encompasses a progressive group of disorders (i.e., emphysema and chronic bronchitis) that 
cause airflow obstruction and breathing problems.2  
Bronchodilator medications are central to symptom management in COPD. Based on efficacy and side effects, 
inhaled bronchodilators are preferred over oral ones.1 As a result, inhaled ȕ2-agonists being bronchodilatory drugs are 
commonly used for the treatment of this condition. There are several inhaled ȕ2-agonists available. According to the 
duration of bronchodilator effect, they may be either short-acting ȕ2-agonists (SABAs) or long-acting ȕ2-agonists (LABAs).  
In Albania the number of reimbursed drugs is increased over years with different medications belong to inhaled ȕ2-
agonists. The combinations of LABAs and inhaled corticosteroids (ICS), salmeterol plus fluticasone and budesonide plus 
formoterol respectively, have been reimbursed for the first time in 2009. Then the inhaled ultra-LABA, indicaterol, with a 
24-hour duration of bronchodilation has been added in the reimbursed drug list in 2011.  
Inhaled and reimbursed ȕ2-agonists should be prescribed in every case based on the specific protocols. These 
protocols serve as national guidelines in day-to-day medical practice in primary care and are prepared in accordance 
with current international and professional guidelines for appropriate drug use in COPD. Having in consideration the 
changes of  reimbused drug list and also the recommendations of national and international guidelines, the aim of this 
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retrospective study is to evaluate the use patterns of inhaled LABAs versus inhaled SABAs reimbursed in Albania during 
2008-2012 for ambulatory COPD treatment.  
 
2. Materials and Methods 
 
Electronic data on drugs reimbursed for Albanian outpatients with COPD during the years 2008-2012 were taken 
retrospectively from the Albanian Health Insurance Institute database. For this purpose it was used International 
Classification of Diseases, Ninth Revision (ICD-9) and also International Anatomical Therapeutic Chemical (ATC) 
classification system of drugs.  
Reimbursed drugs used for the treatment of outpatients who had a diagnosis of COPD ( ICD-9 codes: 491 (chronic 
bronchitis), 492 (emphysema) and/or 496 (chronic obstructive pulmonary disease, not elsewhere classified), were 
primarily obtained from database. 
Then ȕ2-agonists were selected from all those drugs applying the ATC classification system. This classification 
divides the drugs in groups at five different levels according to the organ or system on which they act and according to 
their chemical, pharmacological and therapeutic properties.3,4 
At the second ATC level, ȕ2-agonists belonged to R03 therapeutic group–drugs for obstructive airway diseases. 
Inhaled ȕ2-agonists were selected from this group, using the codes of lower levels until the fifth level of chemical 
substance. 
ATC/DDD methodology, developed by the World Health Organization, was used to quantify the consumption of 
inhaled ȕ2-agonists in DDD/1000 inhabitants/day and the results were expressed as percentage of annual drug use. It 
was used Microsoft Office Excel Program for all the calculations. The number of COPD outpatients who had taken at 
least a reimbursed medical prescription over a year had been used as the denominator. 
The Defined Daily Dose (DDD) provides a fixed unit of measurement independent of price, currencies, package 
size and strength enabling the researcher to assess trends in drug consumption.4 
The DDDs of plain inhaled products that were objects of this study were taken from the ATC/DDD Index-2012. 
Plain products are defined as preparations containing one active component (including stereoisomeric mixtures).4 
Products containing two or more active ingredients are regarded as combination products. The DDDs assigned for 
combination products are based on the main principle of counting the combination as one daily dose, regardless of the 
number of active ingredients included in the combination.4 For combined products, the DDDs were taken from List of 
DDDs for combined products which is available on the website www.whocc.no 
 
3. Results 
 
The total consumption of inhaled ȕ2-agonists reimbursed for the treatment of COPD in primary care in Albania was 
increased during 2008-2012. Although short- and long-acting inhaled ȕ2-agonists showed the increasing trends of 
consumption, the rhythm of such increases was different (Figure 1). As a result, their propotions versus the annual 
consumption of inhaled ȕ2 -agonists reimbursed for COPD had changed a lot over five years (Figure 2). 
 
 
 
Figure 1. Utilization of inhaled and reimbursed ȕ2-agonists in COPD in Albania 
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The consumption of long-acting inhaled ȕ2-agonists (LABAs) represented 4%, 9.5%, 25%, 34% and 45% respectively of 
annual consumption of inhaled ȕ2-agonists used for the treatment of COPD in insured outpatients in Albania during 2008-
2012. On the other hand the consumption of short-acting inhaled ȕ2-agonist (SABAs) represented 96%, 90.5%, 75%, 
66% and 55% respectively of the annual consumption of inhaled ȕ2-agonists, used during the same time period and in 
the same outpatients with COPD (Figure 2).  
 
 
Figure 2. Utilization of LABAs versus SABAs in Albanian insured outpatients with COPD 
 
In the pharmacotherapeutical group of LABAs the consumption of their combinations with inhaled corticosteroids (ICS) 
represented 5.2%, 18%, 24% and 23% of annual use of inhaled ȕ2-agonsits reimbursed for COPD treatment in primary 
care.  
The increase of consumption of inhaled ICS/LABA combinations comparing to the use of plain LABAs was more 
evident from 2009 to 2011. In 2012 the consumptions of LABAs, as plain and combined preparations, were almost 
equivalent (Figure 3).  
 
 
Figure 3. Utilization of ICS/LABA combinations vs single LABAs in Albanian insured outpatients with COPD  
 
Formoterol, salmeterol and indicaterol were three single LABAs reimbursed in Albania for ambulatory COPD treatment. 
Indicaterol was recently added to the reimbursed drug list, whereas two other drugs had been previously reimbursed. 
Among these drugs, formoterol had the greatest consumption  from 2009 to 2011. In the meantime salmeterol showed a 
continual decrease in consumption. This inhaled drug represented only 0.4% of annual inhaled ȕ2-agonists consumption 
reimbursed for COPD in 2012. The use of indicaterol was significantly bigger than the consumption of formoterol in 2012. 
Its consumption represented 13.5% of annual inhaled ȕ2-agonists use reimbursed for COPD in primary care, whereas 
formoterol showed 8.1% of this annual consumption. (Figure 4). 
 
 
Figure 4. Utilization of plain LABAs as active substances reimbursed for ambulatory COPD treatment in Albania 
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Among inhaled ICS/LABA combinations, salmeterol plus fluticasone was more used than budesonide plus formoterol in 
two last years. The difference in consumption of these two inhaled combinations was more evident in 2012 when the 
ratio of their utilizations was 14.5 : 8.5.  
 
 
Figure 5-Utilization of ICS/LABA combinations reimbursed for ambulatory COPD treatment in Albania 
 
4. Discussion 
 
As COPD is a progressive disease, guidelines including those of Global Initiative for Chronic Obstructive Lung Disease 
(GOLD)1,  the American Thoracic Society/European Respiratory Society (ATS/ERS)5 and the National Institute for Health 
and Clinical Excellence6 recommend an escalation of drug therapy with increasing severity of COPD, starting with short-
acting inhaled bronchodilators used on as-needed basis, proceeding to scheduled administration of long-acting inhaled 
bronchodilators, and finally advancing to inhaled corticosteroids in patients with severe or very severe disease with 
frequent exacerbations. (Table 1). However, based on recent findings of the TORCH study that salmeterol plus 
fluticasone is associated with a reduced rate of exacerbations, improved lung function and health-related quality of life, 
and possible survival benefits, European regulatos recently approved its use in patients with milder COPD (FEV1 < 60% 
of predicted pre-bronchodilator value and history of exacerbations).7 
 
Table 1: Recommended Therapy at Each Stage of COPD1 
 
COPD 
Stage FEV1 
Influenza 
Vaccination 
Short-acting 
Bronchodilators 
Long-acting 
Bronchodilators 
Inhaled 
Glucocorticosteroids 
I - Mild FEV180% of predicted ¥ ¥  
II - 
Moderate 50%FEV1<80% of predicted ¥ ¥ ¥  
III - 
Severe 30%FEV1<50% of predicted ¥ ¥ ¥ ¥ 
IV - Very 
Severe 
FEV1<30% of predicted or 
FEV1<50% of predicted plus 
chronic respiratory failure 
¥ ¥ ¥ ¥ 
FEV1, forced expiratory volume in 1 second 
 
Short-acting inhaled bronchodilators have a rapid onset of action and are recommended as rescue medication for all 
severities of COPD to relieve acute symptoms of bronchospasm.8 On the other hand their bronchodilatory effect lasts for 
4-6 hours, so they are not convenient for the maintained therapy. Salbutamol, the “gold standart” fast-acting rescue 
medication,9 which takes effect within a few minutes (1 to 5 minutes) from dosing is the alone SABA reimbursed in 
Albania. Its consumption, as percentage of annual inhaled ȕ2-agonists use, has decreased from 2008 to 2012, because 
this drug provides only short-term relief from COPD symptoms (Figure 2). 
The total use of reimbursed LABAs in treating COPD outpatients is gradually increased during five years. LABAs 
are recommended as first-line agents for maintenance therapy in patients with moderate to very severe disease and 
those with daily symptoms, based on the prolonged duration of action of 12 or more hours. These bronchodilators have 
been shown to improve symptoms, health-related quality of life and lung function, and reduce exacerbations and 
hospitalisations. 10,11 
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Formoterol, salmeterol and indicaterol reimbursed as plain LABA preparations represent different utilizations in 
COPD. Formoterol is more preferred than salmeterol. The bronchodilator effect of both drugs lasts for approximately 12 
hours, but formoterol has a faster onset of action. Studies report prolonged and rapid bronchodilation of formoterol with 
an onset of action at around 5 min, which is comparable with salbutamol and faster than salmeterol and which reaches 
peak bronchodilation within 1 hour.12-14 Because of formoterol's fast onset of action, it has a potential role for use as both 
a rescue and maintenance medication.15  
Indicaterol is a novel, inhaled once-daily ultra-LABA16 for the treatment of COPD. It is likely that once-daily dosing 
of a LABA, which is indicarol in this case, will lead to enhancement of compliance with therapy and may have advantages 
leading to improved overall clinical outcomes in patients with COPD. Furthermore, in preclinical studies, the onset of 
action of indicaterol was similar to that of salbutamol and of formoterol, and was significantly faster than that of 
salmeterol.17 
The numerous priorities of indicaterol related with 24-hour duration of bronchodilation,18 fast onset of action and a 
good overall safety and tolerability profile19 explain why this drug has earned an important place in the current 
management of Albanian COPD outpatients as the most used single LABA and the third most used inhaled ȕ2-agonist, 
after salbutamol and salmeterol plus fluticasone combination in 2012. 
 
 
 
Figure 6. Utilization of inhaled ȕ2-agonists reimbursed for COPD treatment in Albania in 2012 
 
LABAs had been preferred to be used in combination with inhaled corticosteroids (ICS). Inhaled ICS/LABA combinations 
represent 23% of inhaled ȕ2-agonist consumption reimbursed for treating COPD in primary care in 2012. 
Guidelines recommend adding an ICS to long-acting bronchodilator therapy, for patients with with COPD stages 
III-IV and a history of repeated exacerbations.1  The physiological and clinical benefits of LABAs have been shown to be 
enhanced when administered in conjunction with ICS.20,21 There is an excisting possibility that the observed benefit from 
combining these two classes of drugs might be due to a synergistic interaction with the resulting synergic effect being 
greater than the sum of responses achieved from each drug alone.22 Furthermore, single inhaler ICS/LABA is an 
appropriate choice when both agents are needed and may result in better treatment adherence.23,24 
Based on different pharmacological and clinical priorities, formoterol tends to be used as single and combined 
preparations almost equally in 2012. Salmeterol, as a LABA with more prolonged onset of action, is used nearly totally in 
combination with fluticasone propionate in one single inhaler during five years.  
 
5. Conclusion 
 
LABAs consumption is increased much more than the use of SABAs for Albanian insured outpatients with COPD during 
2008-2012. LABAs are generally used with ICS combined in one single inhaler as these combinations have greater 
efficacy than either of their components used alone and are associated with an improved compliance to the therapy. 
Among plain LABAs, indicaterol has reached a significant use in 2012 being an ultra-LABA with 24–hour bronchodilation 
and associated with a better patient’s adherence as an once-daily therapy. This trend of utilization of reimbursed inhaled 
ȕ2-agonists for the ambulatory treatment of COPD in Albania refered to the international guidelines which recommend 
SABAs for as-needed symptom relief and LABAs as long-term maintenance therapies. At last, it can be concluded that 
inhaled ȕ2-agonists added up recently in the Albanian list of reimbursed drugs and which represent advanced 
pharmacological therapies have made possible a contemporary management of COPD outpatients. 
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